The efficacy of current treatments using "cocktails" which include Glaxo's Retrovir and Epivir drugs was confirmed at a conference in Washington over the weekend, but the tendency for the virus to mutate has hampered their effects. The new programme will involve Glaxo acquiring so-called GeneChips from Affymetrix, which enable genetic information on HIV to be correlated with the effects of drugs and the patient's health. If an initial database proves successful, it will be expanded to collect information on "tens of thousands" of HIV-infected patients.
James Niedel, Glaxo's research and development director, said: "By bringing the scientific advances made in the field of genetics to bear on the most difficult questions in the clinic, we hope to be able to improve the current utilisation of anti-HIV therapies in a way that will benefit patients through tailor-made treatment approaches."Reuse content